BeyondSpring is trading 11.29% up at $0.69 on November 4, 2026; no new company-specific announcement or confirmed catalyst was identified. - Major indexes were sharply higher, while biotech ETF XBI was up about 2.1%. These moves are plausible context, but do not establish the direct cause of BeyondSpring’s gain. - The FDA Fast Track designation and trial-funding transaction were announced on September 29 and are prior context, not a confirmed explanation for the move.